2017 American Transplant Congress
Clinical Outcomes of Kidney Transplant Recipients by Steroid Early Withdraw Protocol with Basiliximab Induction.
Urology, Hokkaido University Hospital, Sapporo, Japan
[Purpose] Several steroid early withdrawal protocols (SEWD) have been attempted in recent decades to avoid steroid related adverse effects among kidney transplant recipients. However, there…2017 American Transplant Congress
Time to First Therapeutic Tacrolimus Level: What Impact Does It Have After Heart Transplantation?
University of Pittsburgh Medical Center, Pittsburgh, PA
Purpose: Appropriate time to therapeutic immunosuppression levels is not well defined. The purpose of this study is to investigate outcomes related to time to therapeutic…2017 American Transplant Congress
Generation of Potent Monocytic Myeloid-Derived Suppressor Cells from Rhesus Macaque Bone Marrow.
Surgery (Transplant), University of Pittsburgh, Pittsburgh, PA
Background: Myeloid-derived suppressor cells (MDSC) have shown promise in inhibiting allograft rejection and in promoting transplant tolerance in rodent models. We recently reported that monocytic…2017 American Transplant Congress
One Year Outcomes of Low-Dose vs Very Low-Dose Extended-Release Tacrolimus/Mycophenolate mofetil in De Novo Kidney Transplantation: A Multi-Center Randomized Controlled Trial.
Purpose: Once-daily tacrolimus extended-release formulation (TACER) has now been widely accepted in kidney transplant field. However, the optimal dosage for TACER is still not known.Patients…2017 American Transplant Congress
Risks Associated with Recombinant IL2 Therapy in Renal Transplantation.
Brigham and Women's Hospital, Boston
Regulatory T cells are critical to allograft survival. We report a pilot study of safety and tolerability of low dose recombinant IL2 (rIL2), 1x106 units/m2/day…2017 American Transplant Congress
National Variation in Liver Transplant Immunosuppression in the U.S..
Variation in immunosuppression (ISx) for liver transplant (LTx) across US programs has not been described. We examined a novel database integrating national registry and pharmacy…2017 American Transplant Congress
Risk Factors for Post-Transplant Lymphoproliferative Disorders in Epstein-Barr Virus Mismatch Lung Transplant Recipients.
Brigham and Women's Hospital, Boston
Background: Post-transplant lymphoproliferative disorders (PTLD) are associated with significant morbidity and morality. Lung transplant patients appear to have higher rates of PTLD than other solid…2017 American Transplant Congress
In Clinic Systems to Address Adherence Barriers Decrease Late Allograft Rejection for Kidney Transplant Patients.
Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background: Patient-identified barriers to taking immunosuppressive medications are associated with rejection and allograft loss in kidney transplant patients, yet interventions targeting adherence barriers are rarely…2017 American Transplant Congress
Co-Stimulation Blockade to Minimize and Withdraw Long Term Calcineurin Inhibitors (CNI) in Simultaneous Pancreas and Kidney Transplant (SPK).
The NIH multicenter CTOT-15 trial tested the hypothesis that use of belatacept (bela) could minimize or eliminate long-term CNI use in simultaneous pancreas and kidney…2017 American Transplant Congress
A Promising MyD88 Inhibitor TJ-M2010-2 Protects Heart from Myocardial Ischemia Reperfusion Injury.
BACKGROUND: The activation of innate immunity via myeloid differentiation factor 88 (MyD88) contributes to myocardial ischemia reperfusion injury (IRI). This study is to investigate the…
- « Previous Page
- 1
- …
- 95
- 96
- 97
- 98
- 99
- …
- 138
- Next Page »